Drug
Plozasiran
Plozasiran: highest development phase Approved, developed by Arrowhead Pharmaceuticals, United Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Arrowhead Pharmaceuticals, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| REDEMPLO | Approved | |
| Plozasiran Injection NCT06347003 | Phase 3 | Severe Hypertriglyceridemia |
| Plozasiran NCT05089084 | Phase 3 | Familial Chylomicronemia |
| Plozasiran NCT05902598 | Phase 3 | Familial Chylomicronemia Syndrome |
| Plozasiran Injection NCT06822790 | Phase 3 | Hypertriglyceridemia |
| Plozasiran Injection NCT06347133 | Phase 3 | Hypertriglyceridemia |
| Plozasiran NCT06880770 | Phase 3 | Severe Hypertriglyceridemia |
| Plozasiran Injection NCT06347016 | Phase 3 | Severe Hypertriglyceridemia |
Latest
No recent events.
Follow Plozasiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.